Skip Navigation
Print This Page
Share this page: More

Drug Screens and Evaluations

A major goal of our laboratory is to identify small molecules that inhibit the mutations that we identify in our cancer genomics projects. Starting with known medicinal compounds, we are studying which compounds and modes of delivery might be best for inhibiting glioblastomas and medulloblastomas. Often there are no effective drugs for inhibiting the pathways and mutations we find altered in brain cancers.

Due to this dire need for new and useful drugs, we have started our own small-molecule screening program. We have assembled over 30,000 different pure small molecule compounds in the laboratory, and use these for high-throughput cell based screen. Using cells engineered with cancer-causing mutations and reporter systems that can be adapted to high throughput screens, we have already identified several leads that inhibit genes in the EGFR and AKT pathways. In addition to the small molecule screens we are collaborating with Research Triangle Institute and Mycosynthetix to screen a diverse natural compound library.

transcription of genes for anti-apoptosis, invasion, growth
Transcription of genes for anti-apoptosis, invasion, growth

Lab Team Members

Principal Investigator:
Dr. Gregory Riggins

Dr. Renyuan Bai
Dr. Bilson Baia
Dr. Gary Gallia
Dr. I-Mei Siu

Research Fellow:
Dr. Joshi Avadhut

Administrative Staff:
Ms. Brenda Raymond

Out-of-State and International Patients - Find Out More


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.